STOCK TITAN

Point72, Steven A. Cohen disclose 9.9% stake in Q32 Bio (QTTB)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Q32 Bio Inc. ownership disclosure: Point72 entities and Steven A. Cohen report shared beneficial ownership of 2,057,308 shares, representing 9.9% of the common stock as of the close of business on February 18, 2026.

The cover-page total includes 1,025,654 shares issuable upon exercise of warrants; certain warrants are subject to a verbatim "9.99% Blocker" that limits exercisability and reduces the actual exercisable share count. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen each report shared voting and dispositive power over the reported shares.

Positive

  • None.

Negative

  • None.

Insights

Point72 and Steven A. Cohen report a near-10% holding via warrants and managed funds.

Report lists 2,057,308 shares beneficially owned and a 9.9% class percentage as of February 18, 2026. The cover-page totals include 1,025,654 shares issuable upon exercise of warrants.

The filing states a verbatim "9.99% Blocker" that makes some warrants not presently exercisable; cash-flow treatment and timing for any exercises are not disclosed in the excerpt. Subsequent filings would show whether warrant exercises occur and the actual post-blocker ownership.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Includes 1,025,654 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants (the "Warrants"). As more fully described in Item 4, certain of the Warrants are subject to a 9.99% blocker (the "9.99% Blocker"), and the percentage set forth in row (11) gives effect to such 9.99% Blocker. However, as more fully described in Item 4, the shares of Common Stock reported as being issuable upon exercise of Warrants in rows (6), (8) and (9) include the number of shares of Common Stock that would be issuable upon full exercise of the Warrants and does not give effect to such 9.99% Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such 9.99% Blocker, is less than the number of shares of Common Stock reported in rows (6), (8) and (9) to be issuable upon exercise of the Warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 1,025,654 shares of Common Stock issuable upon exercise of Warrants. As more fully described in Item 4, certain of the Warrants are subject to the 9.99% Blocker, and the percentage set forth in row (11) gives effect to such 9.99% Blocker. However, as more fully described in Item 4, the shares of Common Stock reported as being issuable upon exercise of Warrants in rows (6), (8) and (9) include the number of shares of Common Stock that would be issuable upon full exercise of the Warrants and does not give effect to such 9.99% Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such 9.99% Blocker, is less than the number of shares of Common Stock reported in rows (6), (8) and (9) to be issuable upon exercise of the Warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 1,025,654 shares of Common Stock issuable upon exercise of Warrants. As more fully described in Item 4, certain of the Warrants are subject to the 9.99% Blocker, and the percentage set forth in row (11) gives effect to such 9.99% Blocker. However, as more fully described in Item 4, the shares of Common Stock reported as being issuable upon exercise of Warrants in rows (6), (8) and (9) include the number of shares of Common Stock that would be issuable upon full exercise of the Warrants and does not give effect to such 9.99% Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such 9.99% Blocker, is less than the number of shares of Common Stock reported in rows (6), (8) and (9) to be issuable upon exercise of the Warrants.


SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/19/2026
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/19/2026
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/19/2026
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

What stake does Point72 report in Q32 Bio (QTTB)?

Point72 reports shared beneficial ownership of 2,057,308 shares, equal to 9.9% of common stock as of February 18, 2026. The count includes shares issuable upon exercise of warrants.

How many warrant‑linked shares are included in Point72's filing?

The filing includes 1,025,654 shares issuable upon exercise of warrants. Certain warrants are subject to a "9.99% Blocker" that limits exercisability.

Who is reported as having voting and dispositive power over the shares?

The filing reports shared voting and shared dispositive power held by Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen over the disclosed shares.

What is the effect of the "9.99% Blocker" in the filing?

The filing states the 9.99% Blocker prevents exercise of warrants to the extent such exercise would result in beneficial ownership above 9.99%, so some warrants are not presently exercisable.

Are the reported shares directly owned by Point72 entities or Cohen?

Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen report they own no shares directly; beneficial ownership arises through securities held by Point72 Associates and related arrangements.
Q32 BIO INC

NASDAQ:QTTB

QTTB Rankings

QTTB Latest News

QTTB Latest SEC Filings

QTTB Stock Data

52.54M
9.26M
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM